LogicBio Therapeutics (LOGC) Misses Q2 EPS by 10c

August 13, 2026 4:47 PM EDT

LogicBio Therapeutics (NASDAQ: LOGC) reported Q2 EPS of ($0.14), $0.10 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $33.6 million.

For earnings history and earnings-related data on LogicBio Therapeutics (LOGC) click here.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings

Related Entities

Earnings, Maynard Um, Mark Zuckerberg, ARK